Safety and Immunogenicity of Three V181 Dengue Vaccine Potencies in Adults (V181-003)

NCT05507450 | Completed Phase 2 Results DMC FDA Drug

• 2 other identifiers: V181-0032020-004501-30
• Study Type: interventional
• Target: 1,271
• Locations: 7 countries
• Sites: 32

Brief Summary

The primary objective of this study is to compare the dengue virus-neutralizing antibody geometric mean titers (GMTs) for each of the 4 dengue serotypes (DENV1, DENV2, DENV3, and DENV4) at Day 28 post-vaccination for participants administered the V181 Low-Potency Level vaccine versus the V181 Mid-Potency Level vaccine. This study will also evaluate the safety and tolerability of 3 different V181 potency level vaccines. The primary hypothesis of the study is that the V181 Low-Potency Level vaccine is non-inferior to the V181 Mid-Potency Level vaccine for each of the 4 dengue serotypes based on GMTs at Day 28 post-vaccination.

Conditions

Dengue Disease; Dengue Virus

Outcome Measures

Primary Outcomes (2)

• Dengue Virus-Neutralizing Antibody Titers, as Measured by Virus Reduction Neutralization Test (VRNT)

  A dengue VRNT was conducted to assess neutralizing antibody Geometric Mean Titers (GMTs) for each of the 4 dengue vaccine serotypes (DENV1, DENV2, DENV3, and DENV4) in specimens collected from participants on Day 28 post-vaccination.

  Day 28 post-vaccination

• Percentage of Participants With Vaccine-Related Serious Adverse Events (SAEs)

  An SAE is an AE that results in death, is life-threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. Relatedness of an SAE to the study vaccine will be determined by the investigator.

  Up to 28 days post-vaccination

Secondary Outcomes (2)

• Percentage of Participants With Solicited Injection-Site Adverse Events (AEs)

  Up to 5 days post-vaccination

• Percentage of Participants With Solicited Systemic AEs

  Up to 28 days post-vaccination

Study Arms (4)

V181 High-Potency Level Group

EXPERIMENTAL

Participants will receive a single 0.5mL subcutaneous (SC) dose of V181 High-Potency vaccine.

Biological: V181 High-Potency Level

V181 Mid-Potency Level Group

EXPERIMENTAL

Participants will receive a single 0.5mL SC dose of V181 Mid-Potency vaccine.

Biological: V181 Mid-Potency Level

V181 Low-Potency Level Group

EXPERIMENTAL

Participants will receive a single 0.5mL SC dose of V181 Low-Potency vaccine.

Biological: V181 Low-Potency Level

Placebo

PLACEBO COMPARATOR

Participants will receive a single SC 0.5 mL dose of placebo.

Biological: Placebo

Interventions

V181 High-Potency Level BIOLOGICAL

0.5 mL SC dose of V181 High-Potency vaccine

V181 High-Potency Level Group

V181 Mid-Potency Level BIOLOGICAL

0.5 mL SC dose of V181 Mid-Potency vaccine

V181 Mid-Potency Level Group

V181 Low-Potency Level BIOLOGICAL

0.5 mL SC dose of V181 Low-Potency vaccine

V181 Low-Potency Level Group

Placebo BIOLOGICAL

0.5 mL SC dose of placebo

Placebo

Eligibility Criteria

• Age: 18 Years - 50 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Male participants are eligible to participate if they agree to the following for at least 90 days after administration of study intervention: Abstain from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent; or must agree to use contraception unless confirmed to be azoospermic (vasectomized or secondary to medical cause).
• A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies: Is NOT women of child-bearing potential; or is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of \<1% per year), or is abstinent from heterosexual intercourse as her preferred and usual lifestyle (abstinent on a long term and persistent basis), for at least 90 days after administration of study intervention. (Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.)

You may not qualify if:

• Has known history of dengue or zika natural infection.
• Has an acute febrile illness (temperature ≥38.0°C \[≥100.4°F\] oral or equivalent) occurring within 72 hours before receipt of study vaccine or placebo.
• Has a serious or progressive disease, including but not limited to cancer; uncontrolled diabetes; severe cardiac, renal, or hepatic insufficiency; or systemic autoimmune or neurologic disorder.
• Has known or suspected impairment of immunological function, including but not limited to congenital or acquired immunodeficiency, human immunodeficiency virus (HIV) infection, hematologic malignancy, or treatment for autoimmune diseases.
• Has a condition in which repeated venipuncture or injections pose more than minimal risk for the participant, such as hemophilia, thrombocytopenia, other severe coagulation disorders, or significantly impaired venous access.
• Has a known hypersensitivity to any component of the study vaccine or placebo, or history of severe allergic reaction (eg, swelling of the mouth and throat, difficulty breathing, hypotension or shock) that required medical intervention.
• Has received a dose of any dengue vaccine (investigational or approved) before study entry, or plans to receive any dengue vaccine (investigational or approved) for the duration of the trial.
• Has received other licensed non-live vaccines within 14 days before receipt of study vaccine or placebo, or is scheduled to receive any licensed non-live vaccine within 28 days following receipt of study vaccine or placebo. Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of study vaccine or placebo, or at least 28 days after receipt of study vaccine or placebo.
• Has received a licensed live vaccine within 28 days before receipt of study vaccine or placebo, or is scheduled to receive any live vaccine within 28 days following receipt of study vaccine or placebo.
• Has received systemic corticosteroids (equivalent of ≥2 mg/kg/day of prednisone or ≥20 mg/d for persons weighing \>10 kg) for ≥14 consecutive days and has not completed treatment at least 30 days before study entry or is expected to receive systemic corticosteroids at aforementioned dose and duration within 28 days following receipt of study vaccine or placebo. (Note: Topical and inhaled/nebulized steroids are permitted.)
• Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination.
• Has received immunosuppressive therapies, including chemotherapeutic agents used to treat cancer or other conditions, treatments associated with organ or bone marrow transplantation, or autoimmune disease, within 6 months before receipt of study vaccine or placebo, or plans to receive immunosuppressive therapies within 28 days following receipt of study vaccine or placebo.
• Has received a blood transfusion or blood products (including immunoglobulins) within 6 months before receipt of a study vaccine or placebo, or plans to receive a blood transfusion or blood products (including immunoglobulins) within 28 days following receipt of study vaccine or placebo.
• Has participated in another clinical study of an investigational product within 6 months before signing the informed consent, or plans to participate in another interventional clinical study at any time during the duration of the current clinical study. Participants enrolled in observational studies may be included; these will be reviewed on a case-by-case basis for approval by the Sponsor.
• Has planned donation of blood, eggs, or sperm at any time from signing the informed consent through 90 days post-vaccination.

Sponsors & Collaborators

• Merck Sharp & Dohme LLC: lead

Study Sites (32)

California Research Foundation ( Site 0114)

San Diego, California, 92123, United States

Location

Advanced Medical Research Institute ( Site 0115)

Miami, Florida, 33174, United States

Location

Rochester Clinical Research, Inc. ( Site 0122)

Rochester, New York, 14609, United States

Location

University of Texas Medical Branch ( Site 0113)

Galveston, Texas, 77555, United States

Location

IMA Clinical Research San Antonio ( Site 0111)

San Antonio, Texas, 78229, United States

Location

Alliance for Multispecialty Research LLC (AMR - Norfolk) ( Site 0123)

Norfolk, Virginia, 23502, United States

Location

Paratus Clinical Research Western Sydney ( Site 0007)

Blacktown, New South Wales, 2148, Australia

Location

Emeritus Research ( Site 0010)

Botany, New South Wales, 2019, Australia

Location

USC Clinical Trials Moreton Bay ( Site 0001)

Morayfield, Queensland, 4506, Australia

Location

USC Clinical Trials Sunshine Coast ( Site 0005)

Sippy Downs, Queensland, 4556, Australia

Location

USC Clinical Trials Brisbane (South Bank) ( Site 0006)

South Brisbane, Queensland, 4101, Australia

Location

Emeritus Research ( Site 0009)

Camberwell, Victoria, 3124, Australia

Location

Diex Recherche Quebec Inc. ( Site 0022)

Québec, Quebec, G1V 4T3, Canada

Location

Diex Recherche Joliette ( Site 0023)

Saint-Charles-Borromée, Quebec, J6E 2B4, Canada

Location

Diex Recherche Sherbrooke Inc. ( Site 0024)

Sherbrooke, Quebec, J1L 0H8, Canada

Location

Diex Recherche Victoriavile Inc. ( Site 0021)

Victoriaville, Quebec, G6P 6P6, Canada

Location

FVR, Kokkolan rokotetutkimusklinikka ( Site 0037)

Kokkola, Keski-Pohjanmaa, 67100, Finland

Location

FVR, Oulun rokotetutkimusklinikka ( Site 0032)

Oulu, North Ostrobothnia, 90220, Finland

Location

FVR, Tampereen rokotetutkimusklinikka ( Site 0039)

Tampere, Pirkanmaa, 33100, Finland

Location

FVR, Porin rokotetutkimusklinikka ( Site 0033)

Pori, Satakunta, 28100, Finland

Location

FVR, Seinäjoen rokotetutkimusklinikka ( Site 0040)

Seinäjoki, South Ostrobothnia, 60100, Finland

Location

FVR, Turun rokotetutkimusklinikka ( Site 0031)

Turku, Southwest Finland, 20520, Finland

Location

FVR, Espoon rokotetutkimusklinikka ( Site 0036)

Espoo, Uusimaa, 02230, Finland

Location

FVR, Etelä-Helsingin rokotetutkimusklinikka ( Site 0038)

Helsinki, Uusimaa, 00100, Finland

Location

FVR, Itä-Helsingin rokotetutkimusklinikka ( Site 0035)

Helsinki, Uusimaa, 00930, Finland

Location

Klinikum der Ludwig-Maximilians-Universitaet Muenchen-Division of Infectious Diseases and Tropical (

München, Bavaria, 80802, Germany

Location

Berliner Centrum für Reise- und Tropenmedizin ( Site 0043)

Berlin, 10117, Germany

Location

Bernhard Nocht Institute for Tropical Medicine ( Site 0041)

Hamburg, 20359, Germany

Location

Rambam Health Care Campus-Oncology ( Site 0053)

Haifa, 3109601, Israel

Location

Hadassah Medical Center-Clinical Reaserch Unit ( Site 0052)

Jerusalem, 9112001, Israel

Location

Sheba Medical Center-Early Phase Clinical Trials Unit ( Site 0051)

Ramat Gan, 5265601, Israel

Location

Kaohsiung Medical University Hospital-Infectious diseases Division, Department of Internal Medicine

Kaohsiung City, 807, Taiwan

Location

Related Links

• Merck Clinical Trials Information

Results Point of Contact

• Title: Clinical Trials Disclosure
• Organization: Merck Sharp & Dohme LLC

ClinicalTrialsDisclosure@msd.com

1-800-672-6372

Study Officials

• Medical Director

  Merck Sharp & Dohme LLC

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 17, 2022
• First Posted: August 19, 2022
• Study Start: September 7, 2022
• Primary Completion: June 5, 2023
• Study Completion: May 7, 2024
• Last Updated: May 9, 2025
• Results First Posted: May 9, 2025

Record last verified: 2025-04

Data Sharing

• IPD Sharing: Will share

Locations

US (6); AU (6); FI (9); DE (3); IL (3); TW (1); CA (4)